In TOMORROW’s GEN webinar, Kathleen Davis, Associate Director of Operations at iCura Diagnostics, will describe her experience with validating a highly sensitive dPCR-based LDT for detecting low-frequency BRAF V600E mutations.
In this GEN webinar, Elegen’s Galit Meshulam-Simon, PhD, and Matt Deaner, PhD, will discuss recent innovations in DNA synthesis that enable fast, accurate synthesis of long, complex plasmids.
In this GEN webinar, our speaker, Eric Johansen, PhD, will demonstrate the utility of virion-displayed membrane proteins for screening antibody biologics.
In this GEN webinar, our expert panelists Mark Fielden, PhD, and Jason Apter discussed strategies to overcome challenges in protein quantitation using Ion Mobility Spectrometry, from early R&D through preclinical and clinical trials for gene therapies.
In this GEN webinar, our expert panelists discussed recent insights into the relationship between human genetic variation and disease from functional genomic studies. They shared their preferred strategies for improving payload development and delivery in functional genomics studies using gene editing.
In this GEN webinar, experts from AbbVie and Benchling will share insights into the current tech landscape, AI readiness, and the strategies for digital transformation shaping large and small biopharma.
In this GEN webinar, Dr. Helen Cooper, a leading analytic alchemist from the University of Birmingham, U.K., will discuss improvements in mass spectrometry imaging technology that enable the characterization of the precise protein forms present in multiprotein complexes.
In this GEN webinar, our speakers will present important considerations for quality control testing for biosafety and product characterization in GMP release and stability studies of novel cell and gene therapies.
In this GEN webinar, we will aim to unlock the secrets behind the iterative process development that ensures the highest standards of mRNA manufacturing.
In this GEN webinar, Andrea O’Hara, PhD, a multiomics expert at GENEWIZ from Azenta Life Sciences, will discuss how to use nanopore sequencing technology to enhance the precision and efficiency of cell and gene therapy programs.
In this GEN webinar, experts from Xilis and University of Washington and Plurexa will share results from recent research using patient-derived organoids to study multiple myeloma and polycystic kidney disease.
In this GEN webinar, Mark Stockdale will discuss how the application of synthetic biology and artificial intelligence can be used to improve the safety, potency and manufacturability of gene therapies, and introduce AAV Edge, a comprehensive platform for end-to-end gene therapy optimization—from payload design to production cell lines and model-guided processes.
